MNPR

Monopar Therapeutics Inc

70.54

Oct 26 • 3:59 PM ET -0.11 (-0.16%)

70.50

Aftermarket • 7:42 PM ET -0.04 (-0.06%)

Healthcare Biotechnology USA Small NASD

Peers: ZVRA AKTS TLX RARE RZLT SPRB MIRM RADX ATNM CLRB

| Held by: VTI XBI IWM VXF IWN VTWO IWC VFMO IWO FESM

Scroll to Statements

Index	RUT
Market Cap	473.32M
Enterprise Value	339.13M
Income	-17.84M
Sales	0.00M
Book/sh	19.50
Cash/sh	20.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	22
IPO	Dec 19, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.62
P/C	3.52
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	33.56
Current Ratio	33.56
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.34
EPS next Y	-2.46
EPS next Q	-0.82
EPS this Y	-60.91%
EPS next Y	17.27%
EPS next 5Y	-0.20%
EPS past 3/5Y	23.50% 8.44%
Sales past 3/5Y	- -
EPS Y/Y TTM	29.73%
Sales Y/Y TTM	-
EPS Q/Q	-77.41%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	4.19% -

Insider Own	41.33%
Insider Trans	-1.59%
Inst Own	77.32%
Inst Trans	-0.25%
ROA	-18.90%
ROE	-19.50%
ROIC	-13.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.90%
SMA50	-25.54%
SMA200	-8.53%
Trades

Shs Outstand	6.71M
Shs Float	3.94M
Short Float	27.57%
Short Ratio	5.66
Short Interest	1.09M
52W High	124.82 -43.49%
52W Low	50.07 40.88%
Volatility	3.92% 4.99%
ATR (14)	4.08
RSI (14)	30.62
Beta	1.63
Rel Volume	0.44
Avg Volume	191.86K
Volume	84,714

Perf Week	-1.30%
Perf Month	-17.24%
Perf Quarter	-35.34%
Perf Half Y	30.58%
Perf YTD	8.02%
Perf Year	-13.52%
Perf 3Y	3180.93%
Perf 5Y	205.70%
Perf 10Y	-
Recom	1.30
Target Price	129.91
Prev Close	70.65
Price	70.54
Change %	-0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$119
Jan-09-26	Initiated	Morgan Stanley	Overweight	$115
Nov-14-25	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-25	Initiated	Leerink Partners	Outperform	$115
Oct-13-25	Initiated	Barclays	Overweight	$125
Sep-09-25	Initiated	BTIG Research	Buy	$87
Sep-03-25	Initiated	Raymond James	Strong Buy	$80
Sep-03-25	Initiated	Oppenheimer	Outperform	$77
Aug-26-25	Resumed	H.C. Wainwright	Buy	$70
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight	$74
Jun-23-25	Initiated	Chardan Capital Markets	Buy	$60
Mar-19-25	Resumed	Piper Sandler	Overweight	$76
Jan-10-25	Initiated	Piper Sandler	Overweight	$72
Oct-11-24	Initiated	Rodman & Renshaw	Buy	$50
Jan-28-21	Initiated	ROTH Capital	Buy	$49

Show Previous Ratings

Aug-19-26 08:00AM	Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting 2026 (GlobeNewswire)
Aug-12-26 09:30AM	Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-22-26 08:00AM	Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease (GlobeNewswire)
Jul-20-26 08:00AM	Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team (GlobeNewswire)
Jun-30-26 08:00AM	Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease (GlobeNewswire)
04:05PM	Loading…
Jun-26-26 04:05PM	Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease (GlobeNewswire) +7.85%
Jun-01-26 07:00AM	Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 (GlobeNewswire)
May-19-26 05:33PM	Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease (GlobeNewswire) +17.66%
May-14-26 02:00PM	Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-19-26 07:00PM	Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 (GlobeNewswire)
Mar-27-26 01:00PM	Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-02-26 08:00AM	Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer (GlobeNewswire)
Feb-09-26 01:21PM	Broadcom Stock Sees Improved Relative Strength Rating (Investor's Business Daily)
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)
Nov-13-25 08:00AM	Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments (GlobeNewswire) +5.36%
09:39AM	Loading…
Nov-10-25 09:39AM	Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls (The Fly)
Nov-09-25 09:00AM	Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect? (Zacks)
Oct-16-25 04:33PM	Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy (Insider Monkey) -8.69%
Oct-15-25 08:00AM	Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting 2025 (GlobeNewswire) -5.11%
Sep-23-25 11:08PM	Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.30% +7.94%
11:07PM	Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients (GlobeNewswire)
09:40AM	CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls (The Fly)
Sep-15-25 01:15PM	Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout (Investor's Business Daily) +10.71%
Sep-14-25 08:00AM	Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting (GlobeNewswire)
Sep-03-25 08:00AM	Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting (GlobeNewswire) +6.72%
Aug-12-25 08:00AM	Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments (GlobeNewswire) +14.55%
Jun-26-25 03:24PM	Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy (Insider Monkey) +9.68%
Jun-11-25 09:55AM	Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know (Zacks)
07:00AM	Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers (GlobeNewswire)
09:40AM	Loading…
Jun-06-25 09:40AM	Salesforce initiated, Dollar Tree upgraded: Wall Streets top analyst calls (TipRanks)
Jun-03-25 07:00AM	Monopar Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire) +7.00%
May-13-25 08:00AM	Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments (GlobeNewswire)
May-07-25 02:30AM	Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 (GlobeNewswire)
Apr-30-25 05:37AM	Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 (Insider Monkey)
Apr-29-25 08:00AM	Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 08:00AM	Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments (GlobeNewswire) -9.72%
Mar-21-25 08:50AM	Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going (Zacks) -10.59%
Feb-03-25 07:22PM	Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 (Insider Monkey) +10.22%
Jan-23-25 01:10PM	Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics (PR Newswire) +16.78%
07:06AM	Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright (TipRanks)
Dec-31-24 02:36AM	These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year Heres What Analysts Expect in 2025 (TipRanks) -7.76%
Dec-20-24 09:00AM	Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire) +8.53%
Dec-05-24 04:21PM	Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu (GlobeNewswire) -14.84%
Dec-03-24 08:00AM	Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +5.27%
Nov-08-24 08:00AM	Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments (GlobeNewswire) +7.31%
Oct-30-24 01:42PM	Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) -9.50%
Oct-28-24 09:15PM	Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) +5.32% -9.09%
04:00PM	Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-25-24 07:31AM	Monopar Therapeutics Secures License for Wilson Disease Treatment (TipRanks) -48.16%
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire) +605.40%
Oct-22-24 08:00AM	Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 (GlobeNewswire)
Oct-16-24 08:28AM	Monopar Therapeutics Expands Portfolio with New Patent Filing (TipRanks)
Oct-15-24 08:00AM	Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers (GlobeNewswire)
Oct-08-24 08:30AM	Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial (TipRanks) +5.12%
Oct-07-24 08:00AM	Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers (GlobeNewswire) +10.20%
Sep-12-24 08:00AM	Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr (GlobeNewswire) +64.58%
Sep-04-24 08:00AM	Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 04:05PM	Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.40% -5.83%
Aug-21-24 08:00AM	Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers (GlobeNewswire)
Aug-14-24 08:00AM	Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr (GlobeNewswire) -5.79%
Aug-12-24 12:24PM	Upcoming Stock Splits This Week (August 12 to August 16) Stay Invested (TipRanks) +6.56%
Aug-09-24 02:53PM	MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -19.64%
08:00AM	Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments (GlobeNewswire)
08:00AM	Monopar Therapeutics Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Jul-09-24 07:00AM	Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr (GlobeNewswire)
Jun-25-24 08:00AM	Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24 (GlobeNewswire)
Jun-11-24 07:30AM	Monopar and NorthStar Amend & Extend Collaboration (GlobeNewswire) +5.22%
Jun-10-24 08:00AM	Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 06:15AM	Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely (InvestorPlace)
May-24-24 08:00AM	Monopar Announces CFO Succession (GlobeNewswire)
May-17-24 09:55AM	Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now (Zacks)
May-09-24 01:55PM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19%
07:00AM	Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline (GlobeNewswire)
Apr-18-24 08:00AM	Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 08:00AM	Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings (GlobeNewswire)
Apr-10-24 08:00AM	Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients (GlobeNewswire) +8.36%
Apr-04-24 09:55AM	Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-03-24 12:00PM	All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy (Zacks)
Mar-28-24 11:53AM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.60%
07:00AM	Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments (GlobeNewswire)
Mar-05-24 07:00AM	Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program (GlobeNewswire) +7.06%
Feb-27-24 07:00AM	Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial (GlobeNewswire) -10.37%
Feb-23-24 11:55AM	5 Best Rising Penny Stocks To Buy (Insider Monkey) +16.07%
Feb-22-24 07:00AM	Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers (GlobeNewswire) +96.49%
Feb-20-24 08:00AM	Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers (GlobeNewswire) +95.27%
Nov-09-23 08:37AM	Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs (GuruFocus.com)
07:00AM	Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Nov-01-23 07:00AM	Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire) +27.91%
Oct-10-23 07:00AM	Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -5.96%
Sep-05-23 07:00AM	Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 07:00AM	Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Aug-08-23 07:00AM	Monopar Provides Encouraging Camsirubicin Clinical Data Update (GlobeNewswire) +15.22%
Jul-11-23 07:00AM	Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore (GlobeNewswire)
Jun-21-23 07:00AM	Monopar to Participate in the Radiopharma Forum by the Lake 2023 (GlobeNewswire)
Jun-14-23 07:00AM	Monopar to Participate in the Maxim Groups Healthcare Virtual Conference (GlobeNewswire)
Jun-01-23 07:00AM	Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update (GlobeNewswire) +7.36%
May-29-23 09:55AM	Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-11-23 07:00AM	Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments (GlobeNewswire) -6.58%
Apr-19-23 09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STARR CHRISTOPHER M	Director	Oct 01 '26	Option Exercise	0.01	8,400	42	13,573	Oct 05 05:43 PM
STARR CHRISTOPHER M	Director	Oct 01 '26	Sale	78.50	8,400	659,387	5,173	Oct 05 05:43 PM
CHRISTOPHER STARR	Director	Oct 01 '26	Proposed Sale	79.67	16,800	1,338,456		Oct 01 04:37 PM
Robinson Chandler	Chief Executive Officer	Sep 24 '26	Option Exercise	21.74	29,056	631,680	128,323	Sep 28 08:47 PM
Robinson Chandler	Chief Executive Officer	Sep 24 '26	Sale	88.00	29,056	2,556,851	99,267	Sep 28 08:47 PM
CHANDLER ROBINSON	Director	Sep 24 '26	Proposed Sale	89.38	29,056	2,597,025		Sep 24 04:40 PM
RIOUX PATRICE	Acting Chief Medical Officer	Aug 26 '26	Option Exercise	0.01	1,380	7	5,066	Aug 27 07:29 PM
RIOUX PATRICE	Acting Chief Medical Officer	Aug 26 '26	Sale	111.26	1	111	5,065	Aug 27 07:29 PM
Tsuchimoto Kim R	Director	Aug 26 '26	Sale	111.39	4,090	455,567	7,396	Aug 27 06:28 PM
Anderson Raymond	Director	Aug 25 '26	Sale	111.77	3,142	351,189	23,751	Aug 27 06:27 PM
PATRICE RIOUX	Acting Chief Medical Officer	Aug 26 '26	Proposed Sale	110.82	1	111		Aug 26 04:19 PM
KIM TSUCHIMOTO	Director	Aug 26 '26	Proposed Sale	110.82	8,180	906,508		Aug 26 04:18 PM
RAYMOND WILLIAM ANDERSON	Director	Aug 25 '26	Proposed Sale	111.36	6,284	699,786		Aug 25 04:44 PM
Arthur Klausner	Employer	Jul 07 '26	Proposed Sale	97.05	5,000	485,250		Jul 07 02:28 PM
Vu Quan Anh	Chief Financial Officer	Dec 26 '25	Buy	69.95	1,500	104,925	1,500	Dec 29 12:15 PM
Arthur Klausner	Board Member	Dec 18 '25	Proposed Sale	67.16	5,121	343,903		Dec 19 04:00 PM
KLAUSNER ARTHUR J	Director	Dec 18 '25	Sale	67.15	5,121	343,889	8,762	Dec 19 03:43 PM

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Co-Founder & Independent Executive Chairman of the BoardDr. Christopher M. Starr Ph.D.

M.D.Dr. Chandler D. Robinson M.B.A.

CFOMr. Quan Anh Vu

Chief Operating OfficerMr. Andrew J. Cittadine M.B.A.

Ph.D.Dr. Patrice P. Rioux M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNPR

Monopar Therapeutics Inc

Upgrade your Finviz experience